← Leaderboards
Rakesh C. Kukreja
University Of Central Florida
$21,024,290
Attributed
$26,065,830
Total exposure
11
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.7M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$26,065,830 · 11
By mechanism
R01$21,812,771 · 9
R37$3,787,469 · 1
R25$465,590 · 1
Top collaborators
- Dinender Kumar Singla12 shared
- Anindita Das8 shared
Most similar at University Of Central Florida
Same institution · by research overlap
- Cristina Maria Fernandez-Valle$5,257,998
Others in their field
Top investigators on “Apoptosis”
- David Heimbrook · Leidos Biomedical Research, Inc.$49,205,802
- Jay A Nelson · Oregon Health & Science University$45,942,124
- John C Reed · University Of Texas Md Anderson Can Ctr$34,437,189
- John A Tainer · Scripps Research Institute$30,637,655
- Henry Shelton Earp · Univ Of North Carolina Chapel Hill$28,872,594
- John D Minna · University Of Texas Sw Med Ctr/Dallas$27,317,167
Research focus
ApoptosisSignal TransductionHeartPhosphorylationOxidative StressIn VivoFunctional DisorderPreventAttenuatedProtective EffectCytokineChronicAttenuationSildenafilCyclic Gmp-Dependent Protein KinasesCell DeathCardiac MyocytesErectile DysfunctionPlayGenerationsPharmaceutical PreparationsInhibitor/AntagonistDoxorubicinHeart Failure
Grant awards (65)
Novel Strategy of PDE5-mTOR Inhibition in Attenuation of Cancer Drug Cardiotoxicity$524,060
R01 · FY2025 · HL
Novel Strategy of PDE5-mTOR Inhibition in Attenuation of Cancer Drug Cardiotoxicity$513,579
R01 · FY2024 · HL
Amelioration of Doxorubicin Induced Muscle Dysfunction with Embryoinic stem cells-Derived Exosomes$475,000
R01 · FY2024 · CA
Novel Strategy of PDE5-mTOR Inhibition in Attenuation of Cancer Drug Cardiotoxicity$547,243
R01 · FY2023 · HL · contact PI
Amelioration of Doxorubicin Induced Muscle Dysfunction with Embryoinic stem cells-Derived Exosomes$489,999
R01 · FY2023 · CA
Novel Strategy of PDE5-mTOR Inhibition in Attenuation of Cancer Drug Cardiotoxicity$556,570
R01 · FY2022 · HL · contact PI
BMP-7 Modulates Inflammation induced cell death in Diabetic Cardiac and Skeletal Muscle$586,966
R01 · FY2021 · DK
BMP-7 Modulates Inflammation induced cell death in Diabetic Cardiac and Skeletal Muscle$378,112
R01 · FY2021 · DK
Amelioration of Doxorubicin Induced Muscle Dysfunction with Embryoinic stem cells-Derived Exosomes$132,788
R01 · FY2021 · CA
BMP-7 Modulates Inflammation induced cell death in Diabetic Cardiac and Skeletal Muscle$586,966
R01 · FY2020 · DK
Amelioration of Doxorubicin Induced Muscle Dysfunction with Embryoinic stem cells-Derived Exosomes$566,393
R01 · FY2020 · CA
Amelioration of Doxorubicin Induced Muscle Dysfunction with Embryonic Stem Cell-Derived Exosomes$370,721
R01 · FY2020 · CA
BMP-7 Modulates Inflammation induced cell death in Diabetic Cardiac and Skeletal Muscle$586,966
R01 · FY2019 · DK
Amelioration of Doxorubicin Induced Muscle Dysfunction with Embryoinic stem cells-Derived Exosomes$549,231
R01 · FY2019 · CA
Cardioprotection with mTOR Inhibition$516,135
R01 · FY2019 · HL · contact PI
BMP-7 Modulates Inflammation induced cell death in Diabetic Cardiac and Skeletal Muscle$596,683
R01 · FY2018 · DK
Amelioration of Doxorubicin Induced Muscle Dysfunction with Embryoinic stem cells-Derived Exosomes$557,264
R01 · FY2018 · CA
Cardioprotection with mTOR Inhibition$516,135
R01 · FY2018 · HL · contact PI
Cardioprotection with mTOR Inhibition$516,135
R01 · FY2017 · HL · contact PI
ROS, Inflammation, and Cardioprotection in Type 2 Diabetes$506,155
R01 · FY2017 · HL · contact PI
Cardioprotection with mTOR Inhibition$516,135
R01 · FY2016 · HL · contact PI
ROS, Inflammation, and Cardioprotection in Type 2 Diabetes$505,316
R01 · FY2016 · HL · contact PI
ROS, Inflammation, and Cardioprotection in Type 2 Diabetes$496,910
R01 · FY2015 · HL · contact PI
Protection against Doxorubicin-Induced Cardiomyopathy$393,824
R37 · FY2015 · HL · contact PI
ROS, Inflammation, and Cardioprotection in Type 2 Diabetes$493,566
R01 · FY2014 · HL · contact PI
Protection against Doxorubicin-Induced Cardiomyopathy$391,825
R37 · FY2014 · HL · contact PI
ROS, Inflammation, and Cardioprotection in Type 2 Diabetes$478,664
R01 · FY2013 · HL · contact PI
Cardioprotective Effects of PDE-5 Inhibitors$416,785
R01 · FY2013 · HL · contact PI
Protection against Doxorubicin-Induced Cardiomyopathy$380,630
R37 · FY2013 · HL · contact PI
Cardioprotective Effects of PDE-5 Inhibitors$440,538
R01 · FY2012 · HL · contact PI
Protection against Doxorubicin-Induced Cardiomyopathy$399,821
R37 · FY2012 · HL · contact PI
Cardioprotective Signaling following Phosphodiesterase-5 Inhibition$370,013
R01 · FY2012 · HL · contact PI
Health Educational Research Opportunities (HERO)$93,118
R25 · FY2012 · HL · contact PI
Cardioprotective Effects of PDE-5 Inhibitors$447,575
R01 · FY2011 · HL · contact PI
Protection against Doxorubicin-Induced Cardiomyopathy$427,661
R37 · FY2011 · HL · contact PI
Cardioprotective Signaling following Phosphodiesterase-5 Inhibition$373,750
R01 · FY2011 · HL · contact PI
Health Educational Research Opportunities (HERO)$93,118
R25 · FY2011 · HL · contact PI
Cardioprotective Effects of PDE-5 Inhibitors$448,500
R01 · FY2010 · HL · contact PI
Cardioprotective Signaling following Phosphodiesterase-5 Inhibition$373,750
R01 · FY2010 · HL · contact PI
Protection against Doxorubicin-Induced Cardiomyopathy$354,561
R37 · FY2010 · HL · contact PI
Health Educational Research Opportunities (HERO)$93,118
R25 · FY2010 · HL · contact PI
Cardioprotective Signaling following Phosphodiesterase-5 Inhibition$373,750
R01 · FY2009 · HL · contact PI
Protection against Doxorubicin-Induced Cardiomyopathy$354,561
R37 · FY2009 · HL · contact PI
Health Educational Research Opportunities (HERO)$93,118
R25 · FY2009 · HL · contact PI
CARDIOPROTECTIVE EFFECTS OF PDE-5 INHIBITORS$454,221
R01 · FY2008 · HL · contact PI
Cardioprotective Signaling following Phosphodiesterase-5 Inhibition$372,500
R01 · FY2008 · HL · contact PI
Protection against Doxorubicin-Induced Cardiomyopathy$357,248
R37 · FY2008 · HL · contact PI
Health Educational Research Opportunities (HERO)$93,118
R25 · FY2008 · HL · contact PI
CARDIOPROTECTIVE EFFECTS OF PDE-5 INHIBITORS$450,503
R01 · FY2007 · HL · contact PI
Protection against Doxorubicin-Induced Cardiomyopathy$361,698
R37 · FY2007 · HL · contact PI
CARDIOPROTECTIVE EFFECTS OF PDE-5 INHIBITORS$440,694
R01 · FY2006 · HL · contact PI
Molecular Mechanisms of Delayed Preconditioning$366,188
R01 · FY2006 · HL · contact PI
Protection against Doxorubicin-Induced Cardiomyopathy$365,640
R37 · FY2006 · HL · contact PI
CARDIOPROTECTIVE EFFECTS OF PDE-5 INHIBITORS$454,713
R01 · FY2005 · HL
Molecular Mechanisms of Delayed Preconditioning$375,000
R01 · FY2005 · HL
Molecular Mechanisms of Delayed Preconditioning$375,000
R01 · FY2004 · HL
SIGNALING MECHANISMS IN PHARMACOLOGICAL PRECONDITIONING$290,000
R01 · FY2004 · HL
Molecular Mechanisms of Delayed Preconditioning$375,000
R01 · FY2003 · HL
SIGNALING MECHANISMS IN PHARMACOLOGICAL PRECONDITIONING$290,000
R01 · FY2003 · HL
Molecular Mechanisms of Delayed Preconditioning$375,000
R01 · FY2002 · HL
SIGNALING MECHANISMS IN PHARMACOLOGICAL PRECONDITIONING$290,000
R01 · FY2002 · HL
SIGNALING MECHANISMS IN PHARMACOLOGICAL PRECONDITIONING$290,000
R01 · FY2001 · HL
MOLECULAR MECHANISMS OF DELAYED PRECONDITIONING$265,698
R01 · FY2001 · HL
SIGNALING MECHANISMS IN PHARMACOLOGICAL PRECONDITIONING$281,900
R01 · FY2000 · HL
MOLECULAR MECHANISMS OF DELAYED PRECONDITIONING$258,001
R01 · FY2000 · HL